MMJ is confident that the experienced Harvest One management team will execute on its future business plan and that this should lead to an increase in the value of MMJ’s shareholding in Harvest One.
() holds a 26% interest in () which represents the largest investment within the MMJ cannabis and hemp portfolio.
Harvest One develops and distributes health, wellness, and selfcare products to patients and consumers in regulated markets around the world with a specific focus on sleep, anxiety and pain.
Harvest One’s portfolio of companies
The portfolio companies operate in Canada, the US, Europe, Israel, and the Asia Pacific.
Global footprint
United Greeneries is a vertically integrated licensed producer regulated by Health Canada cultivating premium products for the recreational and medical markets.
Satipharm is Harvest One’s medical and nutraceutical division specialising in the development and manufacturing of cannabinoid-based health and wellness products. Satipharm Gelpell® technology increases bioavailability of CBD and the body's absorption of cannabinoids.
Clinical trials – using Gelpell capsules
Dream water is a natural sleep aid
Delivra is a proprietary transdermal delivery system which shuttles pharmaceutical and natural molecules through the skin in a targeted and specific manner.
Existing and future products
